Geographic variation of mutagenic exposures in kidney cancer genomes

S. Senkin(Centre international de recherche sur le cancer), Sarah Moody(Wellcome Sanger Institute), Marcos Díaz‐Gay(University of California San Diego), Behnoush Abedi‐Ardekani(Centre international de recherche sur le cancer), Thomas Cattiaux(Centre international de recherche sur le cancer), Aida Ferreiro-Iglesias(Centre international de recherche sur le cancer), Jingwei Wang(Wellcome Sanger Institute), Stephen Fitzgerald(Wellcome Sanger Institute), Mariya Kazachkova(University of California San Diego), Raviteja Vangara(University of California San Diego), Anh Le(Wellcome Sanger Institute), Erik N. Bergstrom(University of California San Diego), Azhar Khandekar(University of California San Diego), Burçak Otlu(Middle East Technical University), Saamin Cheema(Wellcome Sanger Institute), Calli Latimer(Wellcome Sanger Institute), Emily Thomas(Wellcome Sanger Institute), Joshua Atkins(University of Oxford), Karl Smith-Byrne(University of Oxford), Ricardo Cortez Cardoso Penha(Centre international de recherche sur le cancer), Christine Carreira(Centre international de recherche sur le cancer), Priscilia Chopard(Centre international de recherche sur le cancer), Valérie Gaborieau(Centre international de recherche sur le cancer), Pekka Keski‐Rahkonen(Centre international de recherche sur le cancer), David Jones(Wellcome Sanger Institute), Jon W. Teague(Wellcome Sanger Institute), Sophie Ferlicot(Assistance Publique – Hôpitaux de Paris), Mojgan Asgari(Iran University of Medical Sciences), Surasak Sangkhathat(Prince of Songkla University), Worapat Attawettayanon(Prince of Songkla University), Beata Świątkowska(Nofer Institute of Occupational Medicine), Sonata Jarmalaitė(Vilnius University), Rasa Sabaliauskaitė(National Cancer Institute), Tatsuhiro Shibata(The University of Tokyo), Akihiko Fukagawa(The University of Tokyo), Dana Mateș(National Institute of Public Health), Viorel Jinga(Carol Davila University of Medicine and Pharmacy), Ștefan Rașcu(Carol Davila University of Medicine and Pharmacy), Mirjana Mijušković(Military Medical Academy), Slaviša Savić(University Hospital Center Dr Dragiša Mišović), Saša Milosavljević, John M.S. Bartlett(Edinburgh Cancer Research), Monique Albert(Ontario Institute for Cancer Research), Larry Phouthavongsy(Ontario Institute for Cancer Research), Patrícia Ashton‐Prolla(Universidade Federal do Rio Grande do Sul), Mariana Rodrigues Botton(Hospital de Clínicas de Porto Alegre), Brasil Silva Neto(Universidade Federal do Rio Grande do Sul), Stephania Martins Bezerra(AC Camargo Hospital), María Paula Curado(AC Camargo Hospital), Stênio de Cássio Zéqui(AC Camargo Hospital), Rui Manuel Reis(Hospital de Câncer de Barretos), Eliney Ferreira Faria(Hospital de Câncer de Barretos), Nei Soares de Menezes(Hospital de Câncer de Barretos), Renata Spagnoli Ferrari(Hospital de Câncer de Barretos), Rosamonde E. Banks(University of Leeds), Naveen Vasudev(University of Leeds), Давид Заридзе(Russian Cancer Research Center NN Blokhin), Anush Mukeriya(Russian Cancer Research Center NN Blokhin), Oxana Shangina(Russian Cancer Research Center NN Blokhin), В. Б. Матвеев(Russian Cancer Research Center NN Blokhin), Lenka Foretová(Masaryk Memorial Cancer Institute), Marie Navrátilová(Masaryk Memorial Cancer Institute), Ivana Holcátová(Charles University), Anna Horňáková(Charles University), Vladimí­r Janout(Palacký University Olomouc), Mark P. Purdue(National Cancer Institute), Nathaniel Rothman(National Cancer Institute), Stephen J. Chanock(National Cancer Institute), Per Magne Ueland(Bevital (Norway)), Mattias Johansson(Centre international de recherche sur le cancer), James McKay(Centre international de recherche sur le cancer), Ghislaine Scélo(Observational & Pragmatic Research Institute), Estelle Chanudet(Radboud University Nijmegen), Laura Humphreys(Wellcome Sanger Institute), Ana Carolina de Carvalho(Centre international de recherche sur le cancer), Sandra Pérdomo(Centre international de recherche sur le cancer), Ludmil B. Alexandrov(University of California San Diego), Michael R. Stratton(Wellcome Sanger Institute), Paul Brennan(Centre international de recherche sur le cancer)
Cited by 73Open Access
Full Text

Abstract

Abstract International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not yet been identified by conventional epidemiology make a substantial contribution to cancer burden 1 . In clear cell renal cell carcinoma, obesity, hypertension and tobacco smoking are risk factors, but they do not explain the geographical variation in its incidence 2 . Underlying causes can be inferred by sequencing the genomes of cancers from populations with different incidence rates and detecting differences in patterns of somatic mutations. Here we sequenced 962 clear cell renal cell carcinomas from 11 countries with varying incidence. The somatic mutation profiles differed between countries. In Romania, Serbia and Thailand, mutational signatures characteristic of aristolochic acid compounds were present in most cases, but these were rare elsewhere. In Japan, a mutational signature of unknown cause was found in more than 70% of cases but in less than 2% elsewhere. A further mutational signature of unknown cause was ubiquitous but exhibited higher mutation loads in countries with higher incidence rates of kidney cancer. Known signatures of tobacco smoking correlated with tobacco consumption, but no signature was associated with obesity or hypertension, suggesting that non-mutagenic mechanisms of action underlie these risk factors. The results of this study indicate the existence of multiple, geographically variable, mutagenic exposures that potentially affect tens of millions of people and illustrate the opportunities for new insights into cancer causation through large-scale global cancer genomics.


Related Papers

No related papers found

Powered by citation graph analysis